SLNO director files Form 3 with no beneficial ownership
Rhea-AI Filing Summary
Soleno Therapeutics (SLNO) filed a Form 3 initial statement for a director as of October 13, 2025. The filing reports no securities beneficially owned, with no non-derivative or derivative holdings listed. It was filed by one reporting person and includes an Exhibit 24 Power of Attorney authorizing the signatory.
Positive
- None.
Negative
- None.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What does SLNO’s Form 3 disclose?
It reports a director with no securities beneficially owned as of October 13, 2025.
What is the event date on the SLNO Form 3?
The event date is October 13, 2025.
Does the SLNO Form 3 list any non-derivative or derivative holdings?
No. No non-derivative or derivative holdings are listed.
How many reporting persons are on this SLNO Form 3?
It was filed by one reporting person.
Does the SLNO Form 3 include a Power of Attorney?
Yes. It includes Exhibit 24 – Power of Attorney.